Jpmorgan Chase & CO Galecto, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024
BUY
$0.6 - $0.89 $1,267 - $1,880
2,113 Added 248.88%
2,962 $2,000
Q4 2023

Feb 12, 2024
SELL
$0.52 - $0.78 $2 - $3
-5 Reduced 0.59%
849 $0
Q2 2022

Aug 11, 2022
SELL
$1.22 - $2.74 $1,112 - $2,498
-912 Reduced 51.64%
854 $1,000
Q1 2022

May 11, 2022
BUY
$1.72 - $3.31 $3,037 - $5,845
1,766 New
1,766 $4,000

Others Institutions Holding GLTO

# of Institutions
1
Shares Held
21.2K
Call Options Held
0
Put Options Held
0
View Full List

About Galecto, Inc.

GLTO Quotes by TradingView
  • Ticker GLTO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,395,700
  • Market Cap $143M
  • Description
  • Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...
More about GLTO
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email